Global Liver Disease Therapeutics Market

1. Summary

The Global Liver Disease Therapeutics Market was valued at $26.3 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.2% CAGR, to an estimated market size of $39.0 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global liver disease therapeutics market encompasses pharmaceutical drugs, biologics, and vaccines designed to treat, manage, or halt the progression of hepatic conditions including viral hepatitis, non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. The scope includes antivirals, immunosuppressants, and targeted therapies, while excluding general organ transplant surgical costs.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Liver Disease Therapeutics Market in the period 2025-30:

• The rising prevalence of metabolic-associated steatotic liver disease (MASLD) is driven by global obesity and diabetes epidemics.
• Recent regulatory approvals of breakthrough therapies, such as Resmetirom for NASH, are creating entirely new multi-billion dollar market segments.
• There is a significant shift toward non-invasive diagnostics, utilizing advanced biomarkers and imaging to replace traditional liver biopsies.
• The market is seeing an expansion of combination therapies to address the multi-factorial nature of chronic liver inflammation and fibrosis.
• Global public health initiatives aimed at eliminating viral hepatitis B and C by 2030 are driving high-volume antiviral drug demand.
• Integration of artificial intelligence in drug discovery is accelerating the clinical pipeline for orphan liver diseases and rare genetic disorders.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: